Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of zasocitinib in moderate-to-severe plaque psoriasis
jRCT2031230583Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in plaque psoriasis (3 arms), sponsored by Takeda. Primary endpoints: Percentage of participants achieving sPGA 0/1 with at least a 2-point decrease from baseline and Percentage of participants achieving PASI-75. Started Nov 2023; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031230583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230583.